NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
globenewswire.com
news
2022-10-17 00:00:00

SANTA ANA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc., a biotechnology company harnessing the power of the body's immune system through the development of natural killer (NK) cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence a Phase 1, open-label, dose-escalation study of its cryopreserved 'off-the-shelf' allogeneic blood-derived NK cell therapy (SNK02) to evaluate safety and tolerability in participants with pathologically confirmed solid tumors refractory to standard of care therapy.
